<DOC>
	<DOCNO>NCT01998607</DOCNO>
	<brief_summary>Osteonecrosis Jaw ( ONJ ) adverse effect antiresorptive therapy well-recognized patient advanced cancer . Detailed information regard risk specify Summary Product Characteristics ( SPC ) . The statement SPC important mechanism minimize risk ONJ . The study objective measure knowledge oncology practitioner prescribe XGEVA® regard content pertain ONJ SPC commercial availability .</brief_summary>
	<brief_title>Survey XGEVA® Presrcibers Europe Evaluate Their Knowledge Summary Product Characteristics Pertaining Osteonecrosis Jaw</brief_title>
	<detailed_description>This multiple cross-sectional survey study practice oncology practitioner prescribe XGEVA Europe across limit 5 large European country population ( include France , Germany , Italy , Spain U.K. ) 4 Nordic country ( Denmark , Finland , Norway Sweden ) . The survey conduct two round . The two survey round conduct 12 18 month 24 30 month XGEVA become commercially available participate country . The initial contact screen potential participate oncology practitioner continue total 210 eligible consent oncology practitioner complete survey per round . For 5 large European country population , intend 30 oncology practitioner survey per country per survey round . If sample size achieve , oncology practitioner another country region survey achieve regional sample size 150 per survey round . Oncology practitioner Nordic country survey achieve regional sample size 60 per survey round . For countires , number survey collect country second survey round , possible , equate number survey collect country first survey round .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Practicing oncology specialist treat least 5 adult patient bone metastasis solid tumour last quarter . Must prescribe XGEVA® within last 12 month . Must participate previous survey round</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Solid tumour</keyword>
	<keyword>Bone Metastasis</keyword>
</DOC>